Agenus Gestione
Criteri Gestione verificati 3/4
Agenus Il CEO è Garo Armen, nominato in Jan1994, e ha un mandato di 32.42 anni. la retribuzione annua totale è $ 1.35M, composta da 53% di stipendio e 47% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1% delle azioni della società, per un valore di $ 1.24M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.7 anni e 3.4 anni.
Informazioni chiave
Garo Armen
Amministratore delegato
US$1.4m
Compenso totale
| Percentuale dello stipendio del CEO | 52.97% |
| Mandato del CEO | 32.4yrs |
| Proprietà del CEO | 1.0% |
| Durata media del management | 3.7yrs |
| Durata media del Consiglio di amministrazione | 3.4yrs |
Aggiornamenti recenti sulla gestione
Recent updates
AGEN: Phase 3 Colorectal Cancer Trial Will Support Bullish Reassessment
Analyst price targets for Agenus have been reaffirmed at $15.50, with modest adjustments to the discount rate, revenue growth assumptions, profit margin and forward P/E reflecting analysts' updated view of the stock's risk profile and earnings potential. What's in the News Agenus is advancing its botensilimab plus balstilimab (BOT+BAL) program with multiple data disclosures, including new Phase 2 results in advanced cutaneous melanoma and published Phase 1b data in treatment refractory hepatocellular carcinoma.AGEN: Phase 3 Colorectal Cancer Trial Will Drive Bullish Reassessment
Analysts now set a higher price target for Agenus, moving their fair value estimate from $12.33 to $15.50, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News Phase 2 data from the C-800-23 study in advanced cutaneous melanoma showed a 22% confirmed objective response rate for botensilimab plus balstilimab, with median overall survival of 16.6 months and a 42% 2 year overall survival rate in the overall cohort, and no treatment related deaths reported (Key Developments).
AGEN: Late Stage Cancer Data And Access Programs Will Drive Future Upside
Analysts have reduced their price targets on Agenus by $8.00 after updating their assumptions for revenue growth, profit margins, and future P/E levels to reflect a more conservative view of the stock’s valuation inputs. What's in the News Agenus is presenting four botensilimab and balstilimab abstracts at the 2026 ASCO Annual Meeting, including first Phase 2 data in advanced cutaneous melanoma and a trial-in-progress update on the Phase 3 CO.33/BATTMAN colorectal cancer study (Key Developments).AGEN: Late Stage Gastrointestinal Cancer Data Will Drive Future Upside
Analysts have nudged their price target on Agenus higher to $8.00, reflecting updated assumptions around discount rates, revenue trends, profit margins, and future P/E expectations. What's in the News Agenus reported Phase II data from a Memorial Sloan Kettering trial combining botensilimab, balstilimab, agenT-797, ramucirumab, and paclitaxel in advanced PD-1 refractory gastroesophageal adenocarcinoma, with a 77% disease control rate in 17 patients and a subset showing survival beyond 20 months (AACR Annual Meeting 2026).AGEN: Expanded Late-Stage Trials And Access Programs Will Drive Future Upside
Analysts have raised their price target on Agenus from $6.00 to $8.00. This reflects updated assumptions around fair value, discount rate, revenue growth, profit margin, and a higher future P/E of 28.67x compared with 19.01x previously.Advanced Immuno-Oncology Therapies Will Reshape Future Cancer Care
The notable upward revision in Agenus’s fair value target is primarily driven by significant improvements in net profit margin and a modest increase in forecasted revenue growth, resulting in a consensus analyst price target increase from $11.00 to $12.33. What's in the News Agenus' botensilimab and balstilimab immunotherapy programs continue to show promising clinical progress, with new survival data and presentations at major oncology congresses, including a 42% two-year survival rate and 21-month median OS in immunotherapy-resistant MSS metastatic colorectal cancer.
BOT/BAL Trials And Cost Reductions Will Shape Future Advances
Strategic cost reduction and asset monetization aim to strengthen financials and fund key projects like BOT/BAL, enhancing potential revenues and earnings.Agenus: Novel Drugs That Just Are Not Novel
Summary Agenus is a small biotech company focused on developing cancer treatments, with a history of poor stock performance and financial struggles. The company's primary assets in its pipeline are Botensilimab and Balstilimab, which have shown limited efficacy in pre-clinical and clinical trials. Recent FDA meeting and phase 2 metastatic colorectal cancer data plummeted AGEN stock 60%, due to discouragement to file for accelerated approval. Further funding is likely to be required soon, considering high cash burn rates and the upcoming phase 3 trial in mCRC. Read the full article on Seeking AlphaThere's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise
Agenus Inc. ( NASDAQ:AGEN ) shareholders are no doubt pleased to see that the share price has bounced 102% in the last...Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results
Shareholders might have noticed that Agenus Inc. ( NASDAQ:AGEN ) filed its quarterly result this time last week. The...Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet
Agenus Inc. ( NASDAQ:AGEN ) shareholders that were waiting for something to happen have been dealt a blow with a 25...Agenus: 2024 May Finally Be The Year For A Major Turnaround
Summary Agenus is a beaten-down immuno-oncology biotech stock that has not participated in the recent biotech rally despite a promising pipeline and multiple partnerships. The company's lead asset, botensilimab (+/- balstilimab), has shown promising results in various advanced solid tumors (colorectal, pancreatic, melanoma, NSCLC, sarcomas, ovarian). A BLA is planned in mid-2024 for accelerated approval in metastatic colorectal cancer with potential for subsequent label expansion to earlier lines. Potential new partnerships are also being evaluated. Cash runway is a concern but planned transactions (sale of 2 assets and monetization of milestones/royalties from partnered programs) in 1H 2024 are expected to considerably extend cash runway. Considering AGEN's track record I am confident about these transactions. Read the full article on Seeking AlphaImproved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet
Agenus Inc.'s ( NASDAQ:AGEN ) price-to-sales (or "P/S") ratio of 2.9x might make it look like a strong buy right now...News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts
Agenus Inc. ( NASDAQ:AGEN ) shareholders will have a reason to smile today, with the analysts making substantial...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$64m |
| Dec 31 2025 | US$1m | US$715k | -US$101k |
| Sep 30 2025 | n/a | n/a | -US$35m |
| Jun 30 2025 | n/a | n/a | -US$166m |
| Mar 31 2025 | n/a | n/a | -US$191m |
| Dec 31 2024 | US$4m | US$715k | -US$227m |
| Sep 30 2024 | n/a | n/a | -US$228m |
| Jun 30 2024 | n/a | n/a | -US$224m |
| Mar 31 2024 | n/a | n/a | -US$240m |
| Dec 31 2023 | US$6m | US$710k | -US$246m |
| Sep 30 2023 | n/a | n/a | -US$271m |
| Jun 30 2023 | n/a | n/a | -US$263m |
| Mar 31 2023 | n/a | n/a | -US$240m |
| Dec 31 2022 | US$6m | US$689k | -US$220m |
| Sep 30 2022 | n/a | n/a | -US$215m |
| Jun 30 2022 | n/a | n/a | US$18m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | US$10m | US$655k | -US$24m |
| Sep 30 2021 | n/a | n/a | US$4m |
| Jun 30 2021 | n/a | n/a | -US$226m |
| Mar 31 2021 | n/a | n/a | -US$190m |
| Dec 31 2020 | US$6m | US$677k | -US$181m |
| Sep 30 2020 | n/a | n/a | -US$174m |
| Jun 30 2020 | n/a | n/a | -US$168m |
| Mar 31 2020 | n/a | n/a | -US$171m |
| Dec 31 2019 | US$10m | US$634k | -US$108m |
Compensazione vs Mercato: La retribuzione totale di Garo ($USD 1.35M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 647.55K ).
Compensazione vs guadagni: La retribuzione di Garo è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Garo Armen (73 yo)
Dr. Garo H. Armen, Ph.D. founded Agenus Inc. in 1994 and has been Chief Executive Officer since 1994 and serves as its Interim Chief Financial Officer & Principal Financial Officer since January 8, 2026. H...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 32.4yrs | US$1.35m | 1.0% $ 1.2m | |
| Chief Medical Officer | 5.4yrs | US$902.82k | 0.14% $ 170.2k | |
| Director and President & CEO of MiNK Therapeutics | 4.4yrs | Nessun dato | 0.044% $ 54.5k | |
| Chief Information Officer | 4.4yrs | Nessun dato | Nessun dato | |
| Vice President of Investor Relations & Corporate Development | 1.6yrs | Nessun dato | Nessun dato | |
| Chief Communications & Government Relations Officer | 1.3yrs | Nessun dato | Nessun dato | |
| Chief People Officer | 4.4yrs | Nessun dato | Nessun dato | |
| Member of Advisory Board & Chief Strategic Advisor | 2.6yrs | Nessun dato | Nessun dato | |
| Chief Commercial Officer | 2.9yrs | Nessun dato | Nessun dato | |
| Head of Medical Affairs | less than a year | Nessun dato | Nessun dato | |
| Scientist II | no data | Nessun dato | Nessun dato | |
| Senior Director of Oncology Strategy & Investor Relations | no data | Nessun dato | Nessun dato |
Gestione esperta: Il team dirigenziale di AGEN è considerato esperto (durata media dell'incarico 3.7 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 27.4yrs | US$1.35m | 1.0% $ 1.2m | |
| Director and President & CEO of MiNK Therapeutics | 2yrs | Nessun dato | 0.044% $ 54.5k | |
| Member of Advisory Board & Chief Strategic Advisor | 3.4yrs | Nessun dato | Nessun dato | |
| Independent Director | 1.8yrs | US$175.04k | 0.094% $ 116.2k | |
| Member of Advisory Board | 3.4yrs | US$1.04m | Nessun dato | |
| Member of Advisory Board | 1.3yrs | US$204.37k | Nessun dato | |
| Independent Lead Director | 19.5yrs | US$199.45k | 0.0066% $ 8.3k | |
| Member of Advisory Board | 3.4yrs | Nessun dato | Nessun dato | |
| Independent Director | 19.3yrs | US$375.32k | 0.011% $ 13.7k | |
| Independent Director | 5.7yrs | US$150.04k | 0.014% $ 17.7k |
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AGEN sono considerati esperti (durata media dell'incarico 3.4 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/17 16:26 |
| Prezzo dell'azione a fine giornata | 2026/06/16 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Agenus Inc. è coperta da 7 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Michael King | Citizens JMP Securities, LLC |
| Emily Bodnar | H.C. Wainwright & Co. |